Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI | Business Wire
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia | Future Oncology
Neratinib for breast cancer – the key is managing gastrointestinal toxicity | Cancer Biology
Puma Biotechnology
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma
FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies - Journal of Thoracic Oncology
Neratinib - Wikipedia
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories - TheStreet
NERATINIB, HKI 272, ..Puma presents positive results from phase II trial of its investigational drug PB272 | New Drug Approvals
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer - ScienceDirect
Puma Biotech presents mixed data on neratinib in glioblastoma
Puma Biotech's Neratinib Fails To Extend Overall Survival In Brain Cancer Trial
Neratinib for HER2-positive breast cancer with an overlooked option | Molecular Medicine | Full Text
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Surging
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 | Business Wire
Mechanism of action | NERLYNX® (neratinib) tablets
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Marketing Application for Early Stage Breast Cancer Therapy Neratinib Submitted to EMA by Puma Biotechnology - Breast Cancer News
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting | Business Wire
Neratinib | 99.94%(HPLC) | In Stock | HER2 inhibitor
